20.10.2024, 938 Zeichen

Valneva: Austrian/French Valneva SE, a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Shigella4V (S4V), the world's most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for which Valneva obtained an exclusive worldwide license from LimmaTech. Fast Track designation is granted by the FDA to products under development that have the potential to treat serious conditions and fill an unmet medical need. It is designed to facilitate the clinical development and expedite the review of important new products with the intention to get them to the people who need them earlier.
Valneva: weekly performance: 5.89%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (17/10/2024)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #799: Bawag-Erfolg um 13 Uhr, Erste knapp davor; Entpolitisierung Finanzministerium und Verwaltungsreform?

Bildnachweis

Aktien auf dem Radar:Porr, Pierer Mobility, UBM, Immofinanz, CA Immo, Addiko Bank, Erste Group, Wienerberger, Bawag, RBI, Wolford, ATX, ATX Prime, ATX TR, Rosgix, AT&S, Kapsch TrafficCom, Linz Textil Holding, Josef Manner & Comp. AG, Marinomed Biotech, RWT AG, voestalpine, Agrana, Amag, EVN, Flughafen Wien, OMV, Palfinger, Österreichische Post, Telekom Austria, Uniqa.

---